Evaluation of association between polymorphism of proxisome proliferator-activated receptor-α and coronary artery calcification in coronary artery disease patients

Document Type : Research Paper

Authors

1 Mashhad university of medical sciences. Mashhad, Iran

2 Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Clinical Pharmacy Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Cardiovascular Diseases, Razavi Hospital, Mashhad, Iran

5 Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Introduction: In previous studies the association between PPARα gene polymorphism and coronary artery calcification (CAC) CAD and atherosclerosis have been demonstrated and, CAD has been shown to be a directly related to CAC. However, an association between PPARα gene polymorphism and CAC has not been studied in our population. The aim of this study was to evaluate a possible association between PPARα gene polymorphisms and  CAC  in CAD patients.
Materials and Methods: A total of Ninety CAD patients and 90 controls enrolled in this study. Computed tomography (CT) angiography was performed for all subjects and CAC was analyzed in the left coronary, left main coronary, right coronary and circumflex arteries. Polymorphism of PPARα was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and possible associations between PPARα polymorphism and coronary artery calcification in CAD patients and healthy controls were investigated.
Results: No significant differences in the allele frequencies (G, C) or genotypes (GG, GC) were found between the two groups (G = 84.6% vs. C = 15.4%; P = 0.52) and (GG = 70.1% vs. GC = 28.9%; P = 0.43), respectively. No significant differences were found between genotype or allele frequencies in patients or healthy control with different CAC (P = 0.41).
Conclusion: No significant association was found between allele – genotype frequencies in subjects with CAC.  

Keywords

References

1.         Mohammadpour AH, Nazemi S, Foroughi M, Ghorbani M, Shamsara J, Behravan J. Evaluation of the association between AT1R1166C polymorphism and the incidence of cad and CAC score in the Iranian population. Arch Biol Sci 2012; 64:401-7.
2.         Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Med 2011; 17:1410.
3.         Hatmi ZN, Tahvildari S, Motlag AG, Kashani AS. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007; 7:32.
4.         Stamler J, Vaccaro O, Neaton JD, Wentworth D, Multiple risk factor intervention trial research group. diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16:434-44.
5.         Lusis AJ. Atherosclerosis. Nature 2000; 407:233-41.
6.         Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, et al. Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 2001; 104:412-7.
7.         Nasir K, Budoff MJ, Shaw LJ, Blumenthal RS. Value of multislice computed tomography coronary angiography in suspected coronary artery disease. J Am Coll Cardiol 2007; 49:2070-1.
8.         Tesche C, De Cecco CN, Stubenrauch A, Jacobs BE, Varga-Szemes A, Litwin SE, et al. Correlation and predictive value of aortic root calcification markers with coronary artery calcification and obstructive coronary artery disease. La Radiol Med 2017; 122:113-20.
9.         Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405:421-4.
10.       Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-88.
11.       Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Int Symposium Neurodegenerat Neuroprot 2006; 34:1341-6.
12.       Lüscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Ann Rev Med 1993; 44:395-418.
13.       Zahra PM, Azizollah AS, Masoud R, Hamed S, Mehrdad H, Ebrahim E. Coronary artery disease in critical patients of Iran. Age 2012; 30:1-6.
14.       Forster BB, Isserow S. Coronary artery calcification and subclinical atherosclerosis: What's the score? Br Columbia Med J 2005; 47:181.
15.       Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscleros Thrombos Vascular Biol 2004; 24:1161-70.
16.       Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, et al. Peroxisome proliferator–activated receptor α gene regulates left ventricular growth in response to exercise and hypertension. Circulation 2002; 105:950-5.
17.       Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, et al. Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105:1440-5.
18.       Purushothaman S, Ajitkumar VK, Renuka Nair R. Association of PPAR 𝜶 intron 7 polymorphism with coronary artery disease: a cross-sectional study. ISRN Cardiol 2011; 2011:816025.
19.       Cresci S. The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Exp Opin Pharmacother 2005; 6:2577-91.
 
 
 
medical journal of mashhad university of medical sciences
Volume 62, Issue 2
May and June 2019
Pages 1420-1429

Files

Share

How to cite

Statistics